TriangleHEALTH PROFESSIONAL · SOURCE READING
Ibrutinib versus ibrutinib plus rituximab versus BR
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (ibrutinib vs. ibrutinib plus rituximab vs. BR):
A prospective trial included 547 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive BR, ibrutinib alone, or ibrutinib plus rituximab.[10]
Source links and citations
A prospective trial included 547 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive BR, ibrutinib alone, or ibrutinib plus rituximab.[10]
With a median follow-up of 38 months, the 2-year PFS rate was 74% for patients who received BR. The rates were significantly higher for patients who received ibrutinib alone (87%; HR, 0.39; 95% CI, 0.25–0.58) or ibrutinib plus rituximab (88%; HR, 0.38; 95% CI, 0.25–0.59; P < .001).[10][Level of evidence B1]
Source links and citations
A prospective trial included 547 previously untreated patients aged 65 years or older. Patients were randomly assigned to receive BR, ibrutinib alone, or ibrutinib plus rituximab.[10]
There was no difference in PFS between the two ibrutinib groups (HR, 1.00; 95% CI, 0.62–1.62; P = .49) and no difference in overall survival (OS) between each of the groups.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice